Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.
Please fill in the details about your medicine requirement on this form.
60/4, T&T House. Yusuf Sarai.
New Delhi:110016 India.
Cetuximab is approved to be used alone or with other drugs to treat (1) Colorectal cancer that has metastasized (spread to other parts of the body). It is used in patients whose disease has the EGFR protein and the wild-type KRAS gene. (2) Squamous cell carcinoma of the head and neck. Distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries.
Global Pharma Network can help you to provide access of Cetuximab medications sold under the brand name for Colorectal cancer treatment by connecting Patients, Health Care Centers, Pharmacies and Retail Outlets with approved supplier, exporter and distributor of Generic drugs, innovator brands and biosimilar medicines from India. Call Mr. Tarun at +91 8744044044 for more details.
The Global Pharma Network is not an online pharmacy company but we help patient to connect with suppliers in the delivering of Colorectal cancer medications a pharmaceutical drug (prescription drug, prescription medication or prescription medicine) that legally requires a medical prescription to be dispensed in following countries as per the customer's prescribed medication and applicable regulatory approval.
International: Epclusa, Harvoni, Vosevi Indian Manaufacturer Brands: Hepcinat (Natco Pharma Ltd.) / Hepcvir (Cipla Limited) / Resof (Hetero Drugs Ltd ) / SoviHep (Zydus Cadila)
Global Pharma Network will help you in importing and exporting this medicine only upon the valid prescription of a licensed medical practitioner and other documents as required by the laws of the jurisdiction in which you are present. USA, UK, Russia, China, India, Nepal, Bhutan, Myanmar / Burma, Laos, Thailand, Cambodia, Hong Kong, Macau, Malaysia, Indonesia, Middle East, Japan, Philippines.